Search clinical trials for: HM10560A

Total 14 results

Hanmi Pharmaceutical Company Limited

Completed

A Study of HM10560A in Healthy Male Subject

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Assess the Safety, Tolerability, and Pharmacokinetic (PK) Characteristics of HM10460A (HNK460) in Healthy Adult Korean Subjects

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Safety and Efficacy Study of Recombinant Human Growth Hormone in Adult Growth Hormone Deficiency Patients (HM10560A)

Adult Growth Hormone Deficiency

Hungary
Hanmi Pharmaceutical Company Limited

Completed

Safety, Pharmacokinetic, Pharmacodynamic Study of LAPS-IFNa in Healthy Adult Subjects

Healthy

Netherlands
Hanmi Pharmaceutical Company Limited

Completed

A Study of HM10760A (Long-acting Erythropoietin) in Healthy Adult Caucasian and Japanese Subjects (EPO)

Healthy

United States
Hanmi Pharmaceutical Company Limited

Completed

Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects

Healthy

United States
Hanmi Pharmaceutical Company Limited

Completed

A Study of HM10760A (Long-acting Erythropoietin (EPO)) in Healthy Korean Subjects

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Terminated

Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Hanmi Pharmaceutical Company Limited

Completed

Molar Potency Study of HM12460A in Healthy Subjects

Healthy Volunteers

United States
Hanmi Pharmaceutical Company Limited

Unknown

Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)

Chronic Hepatitis C Virus Genotype I

Mexico
Hanmi Pharmaceutical Company Limited

Completed

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A (HM12460A)

Healthy | Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
Spectrum Pharmaceuticals, Inc

Completed

Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer

Neutropenia

Australia, Poland, United States, Hungary, Israel, Georgia
Spectrum Pharmaceuticals, Inc

Completed

SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE) (ADVANCE)

Breast Cancer | Neutropenia

United States, Canada, Korea, Republic of
Spectrum Pharmaceuticals, Inc

Completed

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

Breast Cancer | Neutropenia

United States, Canada, India, Hungary, Korea, Republic of, Poland

3

Subscribe